Sharlip 10, Belker AM, Honig S, et al: Vasectomy: AUA guideline. Outcomes of microsurgical vasovasostomy for vasectomy reversal: a meta-analysis and systematic review.n] Urol 188(6 Suppi):2482, 2012
Shinar S, Blecher Y, Alpern S, et al: Total bilateral salpingectomy versus partial bilateral salpingectomy for permanent sterilization during cesarean delivety. Arch Gynecol Obstet295(5):1185, 2017
Shy KK, Stergachis A, Grothaus LG, et al: Tubal sterilization and risk of subsequent hospital admission for menstrual disorders. Am ] Obstet Gynecol 166:n1698,n1992
Society of Gynecologic Oncologists: SGO Clinical Practice Statement: Salpingectomy for ovarian cancer prevention. Available at: https://www.sgo.org/ cl inical-practice/ gu idel i nes/ sgo-cl inical-p ractice-statemen t -sal pi ngecto m yfor-ovarian-cancer-prevention.l Accessed December 13,n2013
Sokal DC, Hieu do T, Loan NO, et al: Contraceptive efectiveness of two insertions of quinacrine: results from 10-year follow-up in Vietnam. Con 8:61, 2008
Sokal DC, Trujillo V, Guzman SC, et al: Cancer risk after sterilization with transcervical quinacrine: updated indings from a Chilean cohort. Contraception 81(1): 5,n2010a
Sokal DC, Vach TH, Nanda K, Quinacrine sterilization and gynecologic cancers: a case-control study in northen Vietnam. Epidemiology 21 (2): 164, 201 Ob
Stuart GS: Puerperal sterilization. In Yeomans ER, Hofman BL, Gilstrap, III, et al (eds): Cunningham and Gilstrap's Operative Obstetrics, 3rd ed. New York, McGraw-Hill, 201
Thompson M, Kho K: Minimally invasive surgery. In Hofman BL, Schorge JO, Bradshaw KD, et al (eds): Williams Gynecology, 3rd ed. New York, McGraw-Hill, 2016
Veersema S, Mijatovic V, Dreyer K, et al: Outcomes of pregnancies in women with hysteroscopically placed micro-inserts in situ. ] Minim Invasive Gynecol 21(3):492, 2014
TERMINOLOGY AND DIAGNOSIS .................. 710
INCIDENCE AND RISK FACTORS ................... 713
ETIOPATHOGENESIS ............................ 713
PATHOPHYSIOLOGY ............................ 717
PREDICTION.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 725
PREVENTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 726
PREECLAMPSIA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 728
ECLAMPSIA. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 734
MANAGEMENT CONSIDERATIONS ................. 738
LONG-TERM CONSEQUENCES .................... 744